Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhaoke Ophthalmology Limited
兆科眼科有限公司
(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

ZHAOKE OPHTHALMOLOGY'S PARTNER TENPOINT THERAPEUTICS, LTD. RECEIVES FDA APPROVAL FOR BRIMOCHOL™ PF IN THE UNITED STATES

This announcement is made by the board of directors (the "**Board**") of Zhaoke Ophthalmology Limited (the "**Company**") on a voluntary basis.

The Board of the Company is pleased to announce that, the Company's partner Tenpoint Therapeutics, Ltd. ("**Tenpoint**") has obtained regulatory approval from the U.S. Food and Drug Administration ("**FDA**") for the commercialization of carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%, which is known as BRIMOCHOL™ PF during clinical trials, and which will have the trade name YUVEZZI™ in the U.S. as an innovative drug for the treatment of presbyopia.

The approval follows Tenpoint's successful Phase 3 clinical trials. The first pivotal Phase 3 BRIO I study demonstrated the benefit of the combination therapy over the individual monotherapy active drug components. In the second vehicle-controlled Phase 3 BRIO II study, BRIMOCHOL™ PF achieved all primary near-vision improvement endpoints with statistically significant three-lines or greater improvement in binocular uncorrected near visual acuity (BUCNVA), without the loss of one line or more in binocular uncorrected distance visual acuity (BUCDVA).

In addition, BRIMOCHOL™ PF was well-tolerated with no serious treatment-related adverse events observed in the over 72,000 treatment days monitored in the BRIO II study. Eye redness was not a commonly reported side effect in clinical trials of the drug. In BRIO I and BRIO II, the reports of adverse events of ocular hyperemia (eye redness) were low. In BRIO II, the rate of reported adverse events of ocular hyperemia (eye redness) was lower in subjects receiving BRIMOCHOL™ PF (2.8%) than carbochol alone (10.7%).

For Zhaoke Ophthalmology, this approval acts as a powerful catalyst for its pre-established commercialization strategy. The Company has built a partnership network for BRIMOCHOL™ PF that now extends to eight commercial partners across Asia-Pacific, including South Korea, Australia, New Zealand, Thailand, Indonesia, the Taiwan/Hong Kong/Macau regions, Singapore, and Vietnam as well as the Middle East. With this FDA endorsement, Zhaoke is anticipated to accelerate the launch of the drug, marking a significant global milestone.

ABOUT BRIMOCHOL™ PF AND BRIO II PHASE 3 STUDY

BRIMOCHOL™ PF is an investigational, preservative-free, once daily eyedrop to correct for the loss of near vision associated with aging. BRIO II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOL™ PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia (NCT05135286). The study enrolled 629 subjects across forty-seven sites in the United States.

ABOUT PRESBYOPIA

Presbyopia is the gradual loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins in adults in their 40s[1] and becomes almost universal by age 50[2]. Presbyopia impacts billions of people globally[3] with approximately 600 million adults affected in China, South Korea and Southeast Asia[4]. In Australia, the total number of prevalence cases reached over 13.5 million in 2023, according to GlobalData[5]. Reading glasses are the most common solution for near-vision correction; however, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. There are currently no approved presbyopia-correcting therapeutics in many countries across the Asia-Pacific region.

ABOUT TENPOINT THERAPEUTICS, LTD.

Tenpoint Therapeutics, Ltd. is a global biotechnology company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally. By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.

1 World report on vision. (2019). Retrieved 29 April, 2022, from https://www.who.int/docs/default-source/documents/world-vision-report-post-launch-accessible.pdf?sfvrsn=1b29f0e7_2

2 Polat, U., Schor, C., Tong, JL. et al. Training the brain to overcome the effect of aging on the human eye. Sci Rep 2, 278 (2012). https://doi.org/10.1038/srep00278

3 Market Scope, Global Presbyopia-Correcting Surgery Market Report. April 2012.

4 Tenpoint Therapeutics data on file

5 GlobalData's Epidemiology Market Size Search extracted on 18 December 2024.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize Atropine Sulfate Eye Drops successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, January 29, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.